Objective: In metastatic gastric cancer (MGC), the goals of treatment are palliation and prolongation of overall survival (OS). Systemic chemotherapy, with docetaxel, cisplatin, infusional 5-fluorouracil(DCF) the most preferred regimen, is the mainstay of the treatment. We evaluated the efficacy and tolerability of weekly DCF (wDCF) compared to standard DCF regimen.
Methods: We retrospectively reviewed 49 and 32 MGC patients treated with DCF and wDCF regimens as first-line treatment, respectively. The wDCF protocol included 25 mg/m² docetaxel, 25 mg/m² cisplatin and 750 mg/m² infusional 5-FU on day 1, every week. Each cycle was repeated every 3 weeks.
Results: The patients in wDCF arm were significantly older (median 54 vs 72.5) and had poor Eastern Cooperative Oncology Group performance status (ECOG PS) than patients in DCF arm (p<0.001). PFS was 3 vs 5 months (p>0.05) and OS was 7 vs 9 months in DCF and wDCF arms (p>0.05), respectively. Overall response rate (ORR) was observed in 28.5% and 31.2% of the patients in DCF and wDCF arms, respectively (p=0.65). Hematologic toxicities were observed more common in wDCF arm.
Conclusions: wDCF is an effective and tolerable regimen and may be an alternative in patients who are elderly and have poor ECOG PS.
Manuscripts that are Published Ahead of Print have been peer reviewed and accepted for publication by the Editorial Board of the West Indian Medical Journal. They may appear in their original format and may not be copy edited or formatted in the style guide of this Journal. While accepted manuscripts are not yet assigned a volume, issue or page numbers, they can be cited using the DOI and date of e-publication. See our Instructions for Authors on how to properly cite manuscripts at this stage. The contents of the manuscript may change before it is published in its final form. Manuscripts in this section will be removed once they have been issued to a volume and issue, but will still retain the DOI and date of e-publication.